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Research
Lung Cancer in a U.S. Population with Low to Moderate Arsenic Exposure
Julia E. Heck,1,2 Angeline S. Andrew,3,4 Tracy Onega,3,4 James R. Rigas,3,5 Brian P. Jackson,6
Margaret R. Karagas,3,4 and Eric J. Duell 1,3,4
1International

Agency for Research on Cancer, Lyon, France; 2School of Public Health and Jonsson Comprehensive Cancer Center,
University of California, Los Angeles, California, USA; 3Norris Cotton Cancer Center, and 4Section of Biostatistics and Epidemiology,
Department of Community and Family Medicine, Dartmouth Medical School, Lebanon, New Hampshire, USA; 5Comprehensive Thoracic
Oncology Program, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA; 6Department of Earth Sciences, Dartmouth
College, Hanover, New Hampshire, USA

Background: Little is known about the carcinogenic potential of arsenic in areas with low to
moderate concentrations of arsenic (< 100 µg/L) in drinking water.
Objectives: We examined associations between arsenic and lung cancer.
Methods: A population-based case–control study of primary incident lung cancer was conducted
in 10 counties in two U.S. states, New Hampshire and Vermont. The study included 223 lung cancer cases and 238 controls, each of whom provided toenail clippings for arsenic exposure measure
ment by inductively coupled–plasma mass spectrometry. We estimated odds ratios (ORs) of the
association between arsenic exposure and lung cancer using unconditional logistic regression with
adjustment for potential confounders (age, sex, race/ethnicity, smoking pack-years, education, body
mass index, fish servings per week, and toenail selenium level).
Results: Arsenic exposure was associated with small-cell and squamous-cell carcinoma of the lung
[OR = 2.75; 95% confidence interval (CI), 1.00–7.57] for toenail arsenic concentration ≥ 0.114 µg/g,
versus < 0.05 µg/g. A history of lung disease (bronchitis, chronic obstructive pulmonary disease,
or fibrosis) was positively associated with lung cancer (OR = 2.86; 95% CI, 1.39–5.91). We also
observed an elevated risk of lung cancer among participants with a history of lung disease and toenail
arsenic ≥ 0.05 µg/g (OR = 4.78; 95% CI, 1.87–12.2) than among individuals with low toenail
arsenic and no history of lung disease.
Conclusion: Although this study supports the possibility of an increased risk of specific lung
cancer histologic types at lower levels of arsenic exposure, we recommend large-scale populationbased studies.
Key words: arsenic, bronchitis, chronic obstructive pulmonary disease, lung cancer, lung diseases,
New Hampshire, pulmonary fibrosis, small-cell carcinoma, smoking, Vermont. Environ Health
Perspect 117:1718–1723 (2009). doi:10.1289/ehp.0900566 available via http://dx.doi.org/ [Online
2 July 2009]

Arsenic in drinking water is a major environmental carcinogen. Worldwide, millions of
people suffer debilitating health effects from
inorganic arsenic exposure, including cancer
and vascular, pulmonary, hematologic, neurologic, and developmental disorders [Heck et al.
2008a; International Agency for Research on
Cancer (IARC) 2004]. In the United States,
an estimated 13 million people are exposed
to arsenic concentrations that exceed the U.S.
Environmental Protection Agency’s (EPA)
maximum contaminant level of 10 ppb (U.S.
EPA 2001).
An increase in the incidence of skin, bladder, and lung cancers at high arsenic concentrations is well established (IARC 2004).
However, the cancer risk from exposure to
lower levels (< 100 µg/L) of arsenic is largely
unknown. The results from other studies have
been inconsistent (Ahsan et al. 2000; Chen
et al. 2004; Ferreccio et al. 1998; Karagas
et al. 2001, 2002; Lamm et al. 2004; Lewis
et al. 1999), perhaps due, in part, to exposure variation in settings where people have
access to noncontaminated water sources.
Inconsistencies in results may also be related to
a lack of information on individual cofactors,
such as smoking or relevant health conditions,
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or to regional differences in factors associated
with arsenic susceptibility, such as nutrition
(Heck et al. 2007, 2009).
Lung cancer is the leading cause of cancerrelated mortality in the United States and
worldwide. IARC (2004) has classified arsenic as a group 1 carcinogen for lung cancer
(IARC 2004). This assessment was based
on studies in which arsenic exposure was
inferred by using area of residence or the arsenic concentration the in well water rather
than using an individual biomarker of exposure (Chen et al.1985, 1986, 1988a, 1988b;
Chen and Wang 1990; Chiou et al. 1995;
Ferreccio et al. 2000; Hinwood et al. 1999;
Hopenhayn-Rich et al. 1998; Lewis et al.
1999; Nakadaira et al. 2002; Rivara et al.
1997; Smith et al. 1998; Tsai et al. 1999;
Tsuda et al. 1995; Wu et al. 1989). The studies not included in the IARC evaluation and
those that have been published since also
have been based on local or regional wellwater concentrations (Baastrup et al. 2008;
Chen et al. 2004; Ferreccio et al. 1998; Guo
2004; Han et al. 2008; Marshall et al. 2007;
Mostafa et al. 2008; Smith et al. 2006).
The use of a biomarker of arsenic exposure may help to improve the assessment of
volume

low-dose health effects, including cancer incidence (Karagas et al. 2002). Trivalent inorganic arsenic binds to the sulfhydryl groups
in nail keratin cells and thus makes toenail
arsenic a reasonable measure of arsenic exposure. Depending on the toe and the speed of
nail growth, toenail measurements represent
exposures that occurred 3–12 months before
sample collection. This finding has been found
to be relatively stable over time (Garland et al.
1993). In this study, we used toenail arsenic
concentration as a biomarker of exposure to
examine the risk of lung cancer among persons
in the U.S. population who had been exposed
to low levels of arsenic in drinking water.

Materials and Methods
The New England Lung Cancer Study
(NELCS), a population-based case–control
study of lung cancer, was conducted in seven
New Hampshire counties (Belknap, Carroll,
Cheshire, Coos, Grafton, Merrimack, and
Sullivan) and in three Vermont counties
(Orange, Windham, and Windsor). We used
the New Hampshire State Cancer Registry,
the Dartmouth-Hitchcock Tumor Registry
of the Norris Cotton Cancer Center, and the
Dartmouth-Hitchcock Medical Center in
Lebanon, New Hampshire, to identify persons from 2005 to 2007 who had received a
clinical diagnosis of lung cancer. We obtained
the names of cases within 1 to 6 months of
their initial diagnosis. Cases who had histologically confirmed primary incident lung
cancer (World Health Organization 2000),
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were between 30 and 74 years of age, resided
in one of the 10 study counties, were alive at
first contact, had a working telephone number,
and were able to communicate in English. Of
the 454 eligible cases, 24 (5%) could not be
reached because of an inaccurate address or
phone number, 52 (11%) were too ill to be
interviewed, and 101 (22%) refused to participate, which yielded 277 subjects and a 61%
participation rate.
Control participants were identified using
a commercial database from Experian for the
contiguous 10-county study area for the period
2005–2006. For each potential control, the
database contained the full name, date of birth
(or estimated age), address, sex, and telephone
number. Using a marginal count comparison
with U.S. Census Bureau data for the same
time period, we identified 73.4% of women
and 72.4% of men in the NELCS study area
in the commercial database. The eligibility of
the controls was based on the same criteria as
that used for cases except for the presence of
lung cancer. Controls were randomly selected
from the commercial database and frequency
matched to lung cancer cases within 5-year age
group and by sex. Of the 547 eligible controls,
123 (22%) could not be reached because of
inaccurate address or phone number, 11 (2%)
were too ill to be interviewed, and 162 (30%)
refused participation. A total of 251 controls
completed the interview for a 46% participation rate. Because self-reported home ownership was somewhat higher among controls
than among cases, we ran all models with
and without a variable for home ownership as
well as educational attainment and household
income to account for potential differences in
these socioeconomic variables.
Study protocol. A letter describing the study
was sent to potential cases and controls informing them of the study and mentioning that a
study interviewer would be contacting them by
telephone within 2 weeks. A prepaid postcard
was included that requested an updated phone
number if the number provided was no longer
valid. At the initial telephone contact, the individual’s name and age were confirmed, verbal
permission obtained, and an interview date
requested. At the in-person interview, written informed consent was obtained from all
participants before participation. The study
complied with all applicable requirements of
the Dartmouth College’s Committee for the
Protection of Human Subjects, the Norris
Cotton Cancer Center, and the State of New
Hampshire for obtaining case names from the
New Hampshire State Cancer Registry. Most
case and control interviews occurred in the participant’s home; some cases were interviewed
in the Norris Cotton Cancer Center or other
location at the participant’s request. All inperson interviews were conducted by trained
interviewers using a structured questionnaire
Environmental Health Perspectives •
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on demographic, lifestyle and medical history;
a 121-item, validated food frequency questionnaire (Salvini et al. 1989); and a lifetime
residential history calendar. The following biological specimens were requested at the interview: a 20-mL blood sample (32% of blood
samples from cases were obtained before initiation of therapy), toenail clippings, an oral buccal brushing, and a Scope (Procter & Gamble
Co., Cincinnati, OH, USA) mouthwash sample, which was used as a source of oral cells for
genomic DNA isolation from those unable or
unwilling to provide a blood sample. In this
study, we used only toenail samples and questionnaire data for the arsenic analysis.
Of the 528 participants, we excluded from
the analysis 62 who did not provide a toenail
sample and 2 (< 1%) whose toenail selenium
could not be analyzed. An additional 3 subjects (< 1%) were excluded because of missing
information on smoking or weight. The final
sample size was 461 participants.
Toenail arsenic analyses. Toenails were
thoroughly washed (and sonicated) with
acetone and Triton-X 100 and rinsed five
times in deionized water to remove exogenous contamination. The nail sample was acid
digested in HNO3 (Optima; Fisher Scientific,
St. Louis, MO, USA) using microwave techniques (Microwave Accelerated Reaction
System 5; CEM Corp., Mathews, NC, USA).
Diluted aliquots of the digested toenail samples were analyzed by collision cell
inductively coupled plasma–mass spectrometry (7500c, Agilent Technologies, Inc., Santa
Clara, CA, USA). Quality control included
assessing the percent recovery of the GBW
07601 hair standard reference material
(National Analysis Center, Beijing, China)
with a certified arsenic value of 0.28 ± 0.04
mg/kg. Our repeated analysis of this reference material (n = 40 > 2 years) gave a value
of 0.235 ± 0.038 (2σ). We also ran repeated
analys es of a second source matrix-spiked
sample (as an initial calibration check and a
continuing calibration check) at a frequency
of every 10 samples and control criteria of
80–120% recovery. Analysis blanks were run
at a frequency of every 20 samples. Digestion
blanks were routinely analyzed and were generally low (< 10 ng/L in the 4× diluted samples).
The mean plus 3 times the standard deviation
(SD) of the digestion blanks was used to determine method detection. The detection limits
are a function of both the method detection
limit and the mass of the nail available for the
digestion. The average sample specific detection limit for arsenic was 0.003 µg/g. For four
persons, the measured arsenic fell below this
limit, and these individuals were assigned an
arsenic value of 0.0015.
Statistical analyses. We analyzed the
demograhic and health characteristics of the
cases and controls and report the odds ratios
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(ORs) of the diseases associated with these
characteristics. Geometric means of toenail
arsenic concentrations were determined and
compared using analysis of variance. Arsenic
exposure has been linked to bronchitis, chronic
obstructive pulmonary disease (COPD), fibrosis, diabetes, and cardiovascular disease (IARC
2004; Mazumder et al. 2005; Smith et al.
2006; States et al. 2009; von Ehrenstein et al.
2005). To describe any potential risk for these
conditions, we provided geometric means for
toenail arsenic concentrations among persons
with and without these diseases. To describe
the possible arsenic sources in this population,
we also determined arsenic concentrations
from drinking water sources and from other
potential exposure routes such as previous
employment in farmwork or woodworking.
We used unconditional logistic regression
analyses to examine the relative risk of lung
cancer with toenail arsenic levels. In the main
analyses, we categorized toenail arsenic into
four levels: < 0.05 µg/g, 0.05 to < 0.0768 µg/g,
0.768 to < 0.1137 µg/g, and ≥ 0.1137 µg/g.
The rationale for this stratification was based on
results from a study of well water and toenail
arsenic from participants in the same region
where Karagas et al. (2000) observed that individuals with toenail arsenic < 0.05 µg/g were
almost uniformly exposed to drinking water
arsenic concentrations of < 1 µg/L. Above that
point, we categorized the participants into
three levels based on the arsenic concentrations among the controls. Because arsenic has
been reported to be associated with squamouscell and small-cell carcinoma, we also analyzed
lung cancer risk by histology (Guo et al. 2004;
Mostafa et al. 2008).
Variables considered for inclusion in the
logistic regression models were those previously
associated with arsenic, with lung cancer incidence, and with interindividual variation in
nail growth (Ahsan et al. 2006; Slotnick and
Nriagu 2006). The analyses also included age,
sex, race/ethnicity, tobacco smoking (packyears), educational attainment (< high school,
high school, > high school), body mass index
(BMI: < 18.5, 18.5 to < 25, ≥ 25), prior selfreported history of arsenic-related lung disease
(bronchitis, COPD, or fibrosis), servings of
fish per week, and selenium intake (quartiles of
toenail concentration; milligrams per kilogram).
We included selenium in the model because
it has been linked to cancer prevention in the
presence of arsenic (Chen et al. 2007). Fish
have trace levels of arsenic, mostly in organic
form, but may also have trace levels of inorganic
arsenic, which in humans, has been linked to
tobacco use and to toenail arsenic concentration (Heck et al. 2008b; Slotnick and Nriagu
2006). Eleven subjects did not complete the
food frequency questionnaire and were assigned
a weekly fish intake equivalent to the mean in
the overall sample (mean, 1.75 servings).
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Because of potential synergistic effects
between arsenic and smoking and between
arsenic and lung disease, we present the
results of models that examined these possible
interaction effects (Chen et al. 2004; Parvez
et al. 2008). We also examined whether a
history of asthma was associated with arsenic
and lung cancer; we found no association and
left this variable out of final models. We also
observed no evidence of an interaction effect
between arsenic and selenium on lung cancer
risk (p = 0.4).

Results
Study subjects were similar in age and sex
(Table 1). The mean age (± SD) was 61.9 ±
9.1 years for cases and 61.0 ± 10.2 years for
controls. Controls smoked less than cases, and
more controls than cases had received education beyond high school. Toenail arsenic
concentrations for the entire study population
ranged from 0.007 to 1.57 µg/g. The distribution of toenail arsenic concentrations was
skewed: 29.1% had arsenic at < 0.05 µg/g,
42.3% between 0.05 and 0.1 µg/g, 18.4%
between 0.1 and 0.15 µg/g, 5.2% between
0.15 and 0.2 µg/g, 4.6% between 0.2 and
0.7 µg/g, and < 1% (two subjects) had arsenic

> 1 µg/g. Toenail arsenic concentrations differed by age, with the highest concentrations
among persons < 70 years of age (Table 1).
Toenail arsenic concentration was positively
associated with fish servings per week and
in controls, it was positively associated with
toenail selenium concentration. The average
length of time at the current residence did not
differ between cases (mean, 17.2 years) and
controls (mean, 16.9 years).
In Table 2, we describe prior lung disease, cardiovascular disease, adult-onset diabetes, and potential sources of arsenic exposure
in the study population in relation to mean
arsenic levels. Among controls, those who
received their water from a nonfiltered well or
spring had higher mean toenail arsenic concentrations than did those who drank filtered
water. Cases who owned their own homes
had higher mean arsenic than did cases who
were not homeowners.
In the multiple regression analyses, higher
toenail arsenic levels were associated with
small-cell carcinoma and squamous-cell carcinoma lung cancer (Table 3). We also observed
an increased risk of lung cancer among those
who reported a prior history of lung disease
(OR = 3.2). With stratification by histology,

we noted that an increased risk of lung cancer
was driven primarily by small-cell carcinoma
cases, although the number of cases in each
histologic group was small (data not shown).
When we examined all lung cancers combined, we found no evidence of an inter
action effect between arsenic exposure and
cigarette smoking in relation to lung cancer
risk (Table 4). When we stratified by selfreported history of lung disease, we observed
an increased risk of lung cancer among
patients with lung disease and toenail arsenic
concentrations > 0.05 µg/g. We obtained similar results when we excluded the two patients
with toenail arsenic > 1 µg/g (data not shown).
Because home ownership was more common among the cases in the Experian database
(80%) than among the cases in the study area
(by county, 68–78%) (U.S. Census Bureau
2008), we examined whether effect estimates
were similar when we limited the analyses to
homeowners (n = 388, 85%), which yielded
similar results to those seen in the overall findings (data not shown).

Discussion
For persons in this study population who were
exposed to low to moderate levels of arsenic

Table 1. Characteristics of the study population and toenail arsenic concentrations.
Arsenic concentration (µg/g)
Cases (n = 223)
Characteristic
Sex
Male
Female
Age (years)
30–49
50–59
60–69
≥ 70
Race/ethnicity
White non-Hispanic
All other ethnicities
Educational attainment
High school graduate or less
Technical school, college, or more
BMI 6 months before interview
17.2–24.9
25–29.9
≥ 30
Smoking (pack-years)
0 (never-smoker)
< 20
21–40
≥ 41
Servings of fish (times per week)
Never or < 1
1 to < 2
2 to < 4
≥4
Selenium quartiles (toenail concentration, mg/kg)
0.05–0.7644
0.7645–0.8901
0.8902–1.075
1.076–5.857

No. (%)

GM (SE)

100 (44.8)
123 (55.2)

0.063 (0.004)
0.071 (0.006)

24 (10.8)
56 (25.1)
90 (40.4)
53 (23.8)

0.081 (0.013)
0.071 (0.007)
0.069 (0.006)
0.054 (0.006)

213 (95.5)
10 (4.5)

0.087 (0.022)
0.066 (0.004)

132 (59.2)
91 (40.8)

0.062 (0.004)
0.074 (0.006)

89 (39.9)
72 (32.3)
62 (27.8)

0.062 (0.005)
0.073 (0.007)
0.066 (0.007)

12 (5.4)
19 (8.5)
49 (22.0)
143 (64.1)

0.065 (0.015)
0.064 (0.011)
0.072 (0.008)
0.065 (0.004)

89 (39.9)
84 (37.7)
32 (14.4)
18 (8.1)

0.057 (0.005)
0.065 (0.005)
0.092 (0.013)
0.085 (0.015)

96 (43.0)
48 (21.5)
47 (21.1)
32 (14.3)

0.066 (0.005)
0.062 (0.007)
0.066 (0.008)
0.077 (0.011)

Controls (n = 238)
p-Value
0.3
0.4

0.3
0.09
0.4

0.9

0.03

0.6

No. (%)

GM (SE)

97 (40.8)
141 (59.2)

0.073 (0.005)
0.074 (0.004)

34 (14.3)
60 (25.2)
82 (34.5)
62 (26.1)

0.076 (0.009)
0.079 (0.007)
0.076 (0.006)
0.063 (0.006)

233 (97.9)
5 (2.1)

0.058 (0.018)
0.076 (0.003)

78 (32.8)
160 (67.2)

0.066 (0.005)
0.077 (0.004)

77 (32.4)
78 (32.8)
83 (34.9)

0.081 (0.007)
0.071 (0.006)
0.068 (0.005)

100 (42.0)
69 (29.0)
36 (15.1)
33 (13.9)

0.072 (0.005)
0.080 (0.007)
0.064 (0.008)
0.075 (0.009)

88 (37.0)
71 (29.8)
59 (24.8)
20 (8.4)

0.070 (0.005)
0.069 (0.006)
0.079 (0.007)
0.088 (0.014)

59 (24.8)
60 (25.2)
60 (25.2)
59 (24.8)

0.056 (0.005)
0.077 (0.007)
0.076 (0.007)
0.087 (0.008)

p-Value
0.8
0.3

0.4
0.1
0.09

0.7

0.03

0.01

Crude odds of
lung cancer associated
with characteristic
[OR (95% CI)]
1.00
0.85 (0.58–1.22)
1.00
1.32 (0.70– 2.50)
1.55 (0.85– 2.84)
1.21 (0.64– 2.29)
1.00
2.19 (0.74– 6.50)
1.65 (1.37– 1.97)
1.00
1.00
0.80 (0.51–1.24)
0.65 (0.41–1.01)
1.00
2.29 (1.05–5.03)
11.3 (5.43–23.7)
36.1 (17.8–73.3)
1.00
1.17 (0.76– 1.80)
0.54 (0.32–0.90)
0.89 (0.44–1.79)
1.00
0.49 (0.30– 0.81)
0.48 (0.29– 0.79)
0.33 (0.19– 0.57)

Abbreviations: GM, geometric mean; CI, confidence interval. p-Values compare mean arsenic concentrations within groups.
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from drinking water, we observed an increased
risk of small-cell carcinoma and squamous-cell
carcinoma lung cancer among participants
with higher arsenic concentrations in toenails. Because of the small sample size of this
study, we recommend that our findings be
interpreted with caution. Not all studies have
observed a varying presentation of histologic
types in the presence of arsenic (Chen et al.
2004). However, a higher risk of squamouscell carcinoma was observed in Bangladesh,
a region with high concentrations of arsenic in the drinking water (up to 366 µg/L)
(Mostafa et al. 2008). Several case reports,
occupational studies, and a published study on
drinking water from Taiwan have all linked
arsenic exposure to small-cell carcinoma of
the lung (Guo et al. 2004; Heddle and Bryant
1983; Kusiak et al. 1993; Lee and Bebb 2005;
Pershagen et al. 1987).
Because we did not collect samples of each
participant’s drinking water, we were unable
to report the risk associated with specific
arsenic concentrations in well water. A geologic survey of the region found that 28% of

private wells in New Hampshire and 6.7%
of wells in Vermont have arsenic concentrations > 5 µg/L (Ayotte et al. 2006). Toenail
arsenic has been correlated with well-water
arsenic concentrations in New Hampshire and
in areas with higher levels of arsenic (Karagas
et al. 2000; Kile et al. 2007). At lower doses,
toenail arsenic concentrations are less likely to
be correlated with concentrations of arsenic in
drinking water due, most likely, to contributions from other exposure sources. A separate investigation of subjects from the same
region found that subjects with toenail arsenic
between 0.05 and 0.5 µg/g had water arsenic concentrations between 1 and 100 µg/L
(Karagas et al. 2000). Besides drinking water
exposure, subjects also may have been exposed
to trace amounts of arsenic from dietary
sources, tobacco, or airborne particle inhalation. We do not anticipate strong effects from
these other sources, because we accounted for
some other exposure sources, such as fish and
smoking, in our multivariate analysis.
We also observed an increased risk of
lung cancer among participants who reported

a prior history of nonmalignant lung disease
(bronchitis, COPD, or fibrosis). A number of
previous studies have linked arsenic exposure
to chronic lung diseases, including shortness
of breath, chest sounds, chronic bronchitis,
bronchiectasis, COPD, and interstitial fibrosis (Guha Mazumder 2007; Mazumder et al.
2005; Milton and Rahman 2002; Milton et al.
2003; Smith et al. 2006; States et al. 2009).
The reported concentrations of water arsenic concentrations in these studies were as
high as > 300 µg/L (Mazumder et al. 2005),
> 400 µg/L (Guha Mazumder 2007), or
1,000 µg/L (Milton and Rahman 2002). In
developing country settings with a wide range of
arsenic concentrations in drinking water, dose–
response effects have been observed between
arsenic levels and chronic cough among both
smokers and nonsmokers (Guha Mazumder
2007; Smith et al. 2006). Although drinking
water arsenic increases both lung disease and
lung cancer rates within the same population
(Smith et al. 2006), to our knowledge, no previous studies have examined a potential synergistic effect, perhaps due in part to the ecologic

Table 2. Toenail arsenic concentrations (µg/g) among study participants, by medical conditions and potential exposure routes.
Arsenic concentration (µg/g)
Characteristic
Ever diagnosed with chronic bronchitis
No
Yes
Ever diagnosed with COPD
No
Yes
Ever diagnosed with fibrosis
No
Yes
Ever diagnosed with asthma
No
Yes
Ever diagnosed with any lung disease (bronchitis,
COPD, or fibrosis)
No
Yes
Ever diagnosed with diabetes
No
Yes
History of cardiovascular disease (ever had coronary
catheterization, angioplasty, heart attack, or stroke)
No
Yes
Primary drinking water source
Public water supply, bottled water drinker, or
subject never drinks water
Well or spring water, filtered
Well or spring water, nonfiltered
Owns own home
No
Yes
Ever employed in farmwork
No
Yes
Ever employed in woodworking
No
Yes

No. (%)

Cases (n = 223)
GM (SE)

188
35

0.065 (0.004)
0.077 (0.010)

193
29

0.067 (0.004)
0.062 (0.009)

219
2

0.066 (0.004)
0.102 (0.057)

183
40

0.065 (0.004)
0.074 (0.009)

173
50

0.066 (0.004)
0.068 (0.008)

192
31

0.067 (0.004)
0.062 (0.009)

183
40

0.067 (0.004)
0.062 (0.008)

124

0.064 (0.005)

34
64

0.063 (0.008)
0.074 (0.007)

50
173

0.055 (0.006)
0.070 (0.004)

185
38

0.068 (0.004)
0.061 (0.008)

213
10

0.065 (0.003)
0.104 (0.026)

p-Value
0.2
0.6
0.5
0.3
0.8

0.6
0.5

0.8

0.03
0.5
0.1

No. (%)

Controls (n = 238)
GM (SE)

225
13

0.074 (0.003)
0.061 (0.012)

232
6

0.074 (0.003)
0.052 (0.015)

236
1

0.073 (0.003)
0.037 (0.026)

206
32

0.072 (0.004)
0.081 (0.010)

221
17

0.075 (0.004)
0.057 (0.010)

216
22

0.075 (0.004)
0.059 (0.009)

200
38

0.074 (0.004)
0.068 (0.008)

111

0.068 (0.005)

50
77

0.070 (0.007)
0.084 (0.007)

23
215

0.061 (0.009)
0.075 (0.004)

169
69

0.078 (0.004)
0.062 (0.005)

225
13

0.073 (0.003)
0.083 (0.016)

p-Value
0.3
0.2
0.2
0.4
0.09

0.09
0.5

0.08

0.2
0.02
0.5

Crude odds of
lung cancer associated
with characteristic
[OR (95% CI)]
1.00
3.22 (1.66–6.27)
1.00
5.81 (2.36–14.3)
1.00
2.16 (0.19–23.9)
1.00
1.41 (0.85–2.33)
1.00
3.76 (2.09–6.74)
1.00
1.59 (0.89–2.83)
1.00
1.15 (0.71–1.87)
1.00
0.61 (0.37–1.01)
0.75 (0.49–1.13)
1.00
0.43 (0.27–0.68)
1.00
0.50 (0.32–0.79)
1.00
0.81 (0.35–1.89)

Abbreviations: GM, geometric mean; CI, confidence interval.
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design of most studies. Differential effects have
been observed in inhalation studies. For example, Chen and Chen (2002) found that Chinese
tin miners with silicosis who were exposed to
arsenic at three mines had an increased risk of
lung cancer, but not at a fourth mine where
arsenic concentrations were lower. In a study
of inhaled arsenic, Taeger et al. (2009) found
that silicosis appeared to be related to the cell
type of lung cancer among the uranium workers who were exposed to arsenic. However, it is
difficult to draw conclusions from these studies
because the mechanism of arsenic-related lung
diseases and lung cancer may differ when arsenic is inhaled rather than ingested.
We did not observe an independent association between arsenic and lung disease in our
cases, suggesting that the possible synergistic
effect should be interpreted with caution. In
other studies, the presence of respiratory symptoms has been reported to be 10–25 times more
common among persons with arsenical dermatosis, even compared with healthy persons living in
the same region who are likely exposed to similar
arsenic concentrations in water (Borgono et al.
1977; De et al. 2004; Guha Mazumder 2007;
Mazumder et al. 2005; Milton and Rahman
2002; Milton et al. 2003). We cannot rule out
the possibility that increased reporting of prior
lung disease among cases (recall bias) may in
part explain these results and ours. Nevertheless,

in a small study, decreases in forced expiratory
volume and forced vital capacity were more
pronounced among persons with arsenicrelated skin cancers than among cancer-free
controls who also were exposed to arsenic in
the drinking water (von Ehrenstein et al. 2005).
However, the greater arsenic concentrations in
those studies make it difficult to directly compare with our results. We recommend further
studies in other populations exposed to low or
moderate levels of arsenic.
Further research is needed to better understand the biologic mechanism by which arsenic affects lung function and lung cancer.
Circulating arsenic is known to be deposited
in the lung, particularly in epithelial tissue.
Arsenic has been associated with both obstructive and restrictive changes in pulmonary
function (Guha Mazumder 2007). Olsen et
al. (2008) found evidence for increased lung
inflammation and inhibition of wound repair
even at low levels of arsenic exposure. As a
carcinogen, mechanisms posited for arsenic
include genetic and epigenetic changes, inhibition of DNA repair, oxidative stress, apoptosis,
and modulation of signal transduction pathways (Andrew et al. 2006; Huang et al. 2004).
In contrast to other studies (Chen et al.
2004; Mostafa et al. 2008), we observed no
interaction between smoking and arsenic
in lung cancer risk. This difference may be

Table 3. Lung cancer in relation to lung disease and arsenic exposure.

Measure
History of lung diseaseb
Never
Ever
Toenail arsenic (µg/g)
< 0.05
0.05 to < 0.0768
0.0768 to < 0.1137
≥ 0.1137

All lung cancers (n = 223)
Cases/controls (n)
OR (95% CI)a

Lung cancer cell types previously
associated with arsenic (small cell and
squamous cell) (n = 75)
Cases/controls (n)
OR (95% CI)a

173/221
50/17

1.00
2.86 (1.39–5.91)

54/221
21/17

1.00
3.21 (1.25–8.24)

65/69
58/66
58/44
57/44

1.00
1.34 (0.71–2.53)
1.10 (0.55–2.20)
0.89 (0.46–1.75)

65/17
58/24
58/13
57/21

1.00
2.99 (1.12–7.99)
1.86 (0.62–5.58)
2.75 (1.00–7.57)

aData

are ORs and 95% confidence intervals (CIs) by logistic regression. Variables are adjusted for each other, as well
as for sex, age, race/ethnicity, educational attainment, BMI, fish servings per week, smoking (pack-years), and seleb
nium. Lung disease includes subjects who were ever diagnosed with bronchitis, COPD, or fibrosis.

Table 4. Toenail arsenic concentrations and lung cancer in relation to smoking and lung disease among
cases (n = 223) and controls (n = 238).
All lung cancers
Arsenic
Exposure
concentration (µg/g)
Cases/ controls
OR (95% CI)
Smoking historya
Never
< 0.05
4/32
1.00
Never
≥ 0.05
8/67
1.03 (0.28–3.75)
Ever
< 0.05
65/33
2.86 (0.83–9.80)
Ever
≥ 0.05
146/106
2.79 (0.87–8.94)
History of lung diseaseb
Never
< 0.05
52/57
1.00
Never
≥ 0.05
121/164
1.02 (0.62–1.69)
Ever
< 0.05
17/8
1.31 (0.45–3.84)
Ever
≥ 0.05
33/9
4.78 (1.87–12.2)
aORs

and 95% confidence intervals (CIs) by logistic regression, with adjustment for sex, age, race/ethnicity, educational
attainment, BMI, lung disease, fish servings per week, smoking (pack-years) and selenium. bModel adjusts for sex, age,
race/ethnicity, educational attainment, BMI, fish servings per week, smoking (pack-years) and selenium. Lung disease
includes subjects who were ever diagnosed with bronchitis, COPD, or fibrosis.

1722

volume

explained by the considerably lower arsenic
concentrations seen in the NELCS area. In the
study by Mostafa et al. (2008), risk estimates
for lung cancer did not differ between smokers
and nonsmokers when arsenic concentrations
were > 100 µg/L.
A strength of this investigation was the
population-based study design and data collection by in-person interview, with detailed information sought about prior medical history. To
our knowledge this study was one of the first
on arsenic and lung cancer that measured arsenic exposure using a biomarker of exposure. In
developed nations, individuals exposed to arsenic in drinking water are likely to have access
to other water sources. Thus, ecologic analyses
of arsenic concentrations in drinking water and
cancer are more likely subject to the ecologic
fallacy than are studies in developing countries.
A limitation of this study was the response
rate difference between cases and controls,
which would be of concern if it led to differential recruitment according to factors related
to arsenic exposure. Controls were selected at
random from persons residing across the study
area. Arsenic concentrations in well water are
known to vary considerably within a small geographic area, with high variation for wells even
less than 100 m apart (Van Geen et al. 2003).
Concentrations also can vary considerably
according to the depth of the well. In addition,
we did not find an association between case status and ZIP code of residence (p = 0.3). Thus,
we do not anticipate that potential geographic
differences between cases and controls would
explain our findings. Given the higher home
ownership among controls, we also examined
whether socioeconomic status could explain
the variation seen in arsenic. Among controls,
arsenic concentrations did not differ by home
ownership (p = 0.2) or by income level (p = 0.9).
Other limitations of this study include
self-reported demographic and medical information that is subject to the biases associated
with that type of data collection. In addition,
although participants had generally been living at the same address for a considerable time
period (mean, 17 years), toenail arsenic concentrations represent exposures that occurred
in the previous year, and our results should be
considered in light of this limitation. Further,
early life arsenic exposures may be potentially
relevant to lung cancer development (Smith
et al. 2006), and the retrospective design of this
study prohibited us from collecting information on earlier exposures. We also did not have
additional biomarkers, such as urinary arsenic
or arsenic species (in urine or toenails), which
could have shed additional light on individual
arsenic methylation and subsequent cancer
risk. An analysis of low-level arsenic exposure
in Slovakia concluded that toenails were more
predictive than urine of arsenic exposure at low
concentrations (Wilhelm et al. 2005).
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Conclusions
We found associations between arsenic exposure and small-cell and squamous-cell carcinoma of the lung. These findings stress the
relevance of evaluating the role of arsenic in
lung cancer development in prospective studies of populations exposed to all arsenic levels.
Further studies in persons at low levels of exposure, which include information on health history, would assist in modifying risk assessment
for the U.S. population and elsewhere.
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